-
govuk-puppet
Discontinued Decommissioned: Puppet manifests that used to provision the legacy GOV.UK stack.
-
InfluxDB
Power Real-Time Data Analytics at Scale. Get real-time insights from all types of time series data with InfluxDB. Ingest, query, and analyze billions of data points in real-time with unbounded cardinality.
Strange for them to send out e-mails on a Sunday, normally it’s a Friday afternoon, answering these 2 questions: Can you please supply: - the metric or standard that is used by the MHRA to quantify the term “safe” with regards/reference to a “covid vaccine” authorised for use by the MHRA? - the metric or standard that is used by the MHRA to quantify the term “effective” with regards/reference to a “covid vaccine” authorised for use by the MHRA? What an answer - they have no definitive standard to measure either safety nor effectiveness of any medicine or vaccine. So how do they know something is “safe” or “effective”? It is because they, or the manufacturer, say it is!!! Here is their actual answer: There is no ‘metric or standard’ used by the MHRA to quantify ‘safe’ in terms of a COVID-19 vaccine, or any other medicinal product. (my highlighting). No medicine is completely risk-free. For a medicine to be considered acceptably safe, its expected benefits should be greater than any associated risks of harmful reactions (my highlighting). This can be determined based on the data submitted with an application for a marketing authorisation for a medicinal product such as a COVID-19 vaccine. But the balance of benefits and risks for any product can change at any time during its marketed life, for example if a serious new side effect is established. For this reason the MHRA continually monitors the safety of all medicinal products authorised in the UK, including the COVID-19 vaccines. The process is termed pharmacovigilance and this involves: monitoring the use of medicines in everyday practice to identify previously unrecognised adverse effects or changes in the patterns of adverse effects assessing the risks and benefits of medicines in order to determine what action, if any, is necessary to improve their safe use providing information to healthcare professionals and patients to optimise safe and effective use of medicines monitoring the impact of any action taken You can read more about the MHRA’s safety assessments for COVID-19 vaccines here Coronavirus (COVID-19) vaccines adverse reactions - GOV.UK (www.gov.uk) As stated above, all medicinal products are authorised based on an assessment of the benefit/risk - that is the benefit to the patient being greater than the known risks associated with taking that product. To understand the assessment of the benefit/risk for each of the Covid-19 vaccines authorised, please refer to the Public Assessment Reports (PARs) for each of the vaccines that we have provided links to in our previous responses to you. Vaccine efficacy is usually measured in randomised controlled clinical trials. It is calculated by comparing the proportion of trial subjects that developed symptomatic COVID-19 in the vaccine arm with the proportion that developed symptomatic COVID-19 in the placebo arm. The calculation is made after a certain number of COVID-19 cases have occurred in the trial as a whole. This number is decided at the start of the trial. This means that a time period is not chosen. More details on the measurement of vaccine efficacy are provided in the PARs that you have already received. We hope this information is helpful. But the PARs they mention do NOT prove the vaccines are safe nor effective when you read them. I have read them many times and cannot find out what in them proves safety and/or effectiveness.
Related posts
-
Help with my income tax calculations, should salary sacrifices be considered as part of the taxable income or not?
-
Should I report suspicious behaviour in my street?
-
Do I need a Transit Visa?
-
Expats - what did you do about your savings accounts when you moved here?
-
I think HR asked me to commit minor VAT fraud